Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Key Highlights
- ➤Stephen Aschettino appointed Senior Vice President and Chief Information Officer
- ➤Aschettino received inducement options for 70,000 shares at $24.61
- ➤Seventeen new employees received options covering 175,920 shares at $24.61
- ➤Options vest over four years and expire after 10 years
- ➤Zorevunersen is being evaluated in a Phase 3 Dravet syndrome study
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on October 15, 2026, it granted stock options to purchase shares of common stock to Stephen Aschettino, the Company’s newly-appointed Senior Vice President, Chief Information Officer, and seventeen other new employees, as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Get started
Create a free account to read the full story.